title: Fractional flow reserve of infarct-related arteries identifies reversible defects on noninvasive myocardial perfusion imaging early after myocardial infarction.
abstract: OBJECTIVE
  We hypothesized that fractional flow reserve (FFR) of an infarct-related artery (IRA) early after myocardial infarction (MI) identifies inducible ischemia on noninvasive imaging.
  
  
  BACKGROUND
  Early after MI, IRAs frequently have angiographically indeterminant lesions. Whether FFR can detect reversible perfusion defects early after MI when dynamic microvascular abnormalities are present is not known.
  
  
  METHODS
  Rest and dipyridamole (DP)-stress 99mTc sestamibi single-photon emission computed tomography (SPECT) were performed in 48 patients 3.7 +/- 1.3 days after MI, with 23 patients undergoing concurrent myocardial contrast echocardiography (MCE). Angiography, FFR, and percutaneous coronary intervention (PCI) of the IRA (as necessary) were subsequently performed. Follow-up SPECT was performed 11 weeks after PCI to identify true reversibility on baseline SPECT.
  
  
  RESULTS
  The sensitivity, specificity, positive and negative predictive value, and concordance of FFR < or =0.75 for detecting reversibility on SPECT were 88%, 50%, 68%, 89%, and 71% (chi-square <0.001), respectively; which improved to 88%, 93%, 88%, 93%, and 91% (chi-square <0.001), respectively, for the detection of true reversibility. The corresponding values of FFR < or =0.75 for detecting reversibility on DP-MCE were 90%, 100%, 100%, 75%, and 93% (chi-square <0.001), respectively, and on either SPECT or MCE were 88%, 93%, 91%, 91%, and 91% (chi-square <0.001), respectively. The optimal FFR value for discriminating inducible ischemia on noninvasive imaging was 0.78.
  
  
  CONCLUSIONS
  Fractional flow reserve of the IRA accurately identifies reversibility on noninvasive imaging early after MI. These findings support the utility of FFR early after MI.
authors.affiliation: Andreas Gruentzig Cardiovascular Center, Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia 30322, USA. hsamady@emory.edu
authors.forename: Habib
authors.initials: H
authors.lastname: Samady
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Lepper
authors.forename: Eric R
authors.initials: ER
authors.lastname: Powers
authors.forename: Kevin
authors.initials: K
authors.lastname: Wei
authors.forename: Michael
authors.initials: M
authors.lastname: Ragosta
authors.forename: Gregory G
authors.initials: GG
authors.lastname: Bishop
authors.forename: Ian J
authors.initials: IJ
authors.lastname: Sarembock
authors.forename: Lawrence
authors.initials: L
authors.lastname: Gimple
authors.forename: Denny D
authors.initials: DD
authors.lastname: Watson
authors.forename: George A
authors.initials: GA
authors.lastname: Beller
authors.forename: Kurt G
authors.initials: KG
authors.lastname: Barringhaus
mesh_terms: D000368:Aged; D003326:Coronary Circulation; D003331:Coronary Vessels / Q000503:physiopathology*; D004176:Dipyridamole; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000503:physiopathology*; D017202:Myocardial Ischemia / Q000175:diagnosis* / Q000503:physiopathology*; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D020127:Recovery of Function; D012680:Sensitivity and Specificity; D017256:Technetium Tc 99m Sestamibi; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D019275:Radiopharmaceuticals; D004176:Dipyridamole; D017256:Technetium Tc 99m Sestamibi